Troglitazone and liver injury
- 1 February 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 41 (2), 237-246
- https://doi.org/10.1002/hep.20567
Abstract
No abstract availableThis publication has 141 references indexed in Scilit:
- Mechanisms of Hepatic Transport of Drugs: Implications for Cholestatic Drug ReactionsSeminars in Liver Disease, 2002
- Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinedionesJournal of Hepatology, 2001
- Involvement of P21Waf1/Cip1, P27Kip1, and P18Ink4c in Troglitazone–Induced Cell–Cycle Arrest in Human Hepatoma Cell LinesHepatology, 2001
- Spontaneous and Thiazolidinedione-Induced B6C3F1 Mouse Hemangiosarcomas Exhibit Low ras Oncogene Mutation FrequenciesToxicology and Applied Pharmacology, 1999
- p53 Is Not Inactivated in B6C3F1 Mouse Vascular Tumors Arising Spontaneously or Associated with Long-Term Administration of the Thiazolidinedione TroglitazoneToxicology and Applied Pharmacology, 1999
- Lack of Effect of Type II Diabetes on the Pharmacokinetics of Troglitazone in a Multiple-Dose StudyThe Journal of Clinical Pharmacology, 1997
- Inhibition of oxidation of low density lipoprotein by troglitazoneAtherosclerosis, 1996
- Stimulation of bile acid 6α-hydroxylation by rifampinJournal of Hepatology, 1996
- Preferential distribution of apoptotic bodies in acinar zone 3 of normal human and rat liverJournal of Hepatology, 1988
- 6α-Glucuronidation of hyodeoxycholic acid by human liver, kidney and small bowel microsomesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1987